ABHD12

Across TCGA pan-cancer cohorts, ABHD12 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ABHD12 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ABHD12 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ABHD12 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA and UCEC are the cancer types where ABHD12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	1.000	0.607	.020	5	view →
UCEC	DFS	Median	All	1.000	0.630	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ABHD12–BLCA (DFS)

Open the BLCA breakdown →